521 related articles for article (PubMed ID: 9592894)
21. Addressing patient concerns about intravenous iron therapy.
Robbins KC
Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary edema: atypical anaphylactoid reaction to intravenous iron dextran.
Freter S; Davidman M; Lipman M; Bercovitch D
Am J Nephrol; 1997; 17(5):477-9. PubMed ID: 9382172
[TBL] [Abstract][Full Text] [Related]
23. Intravenous iron therapy: well-tolerated, yet not harmless.
Sengölge G; Hörl WH; Sunder-Plassmann G
Eur J Clin Invest; 2005 Dec; 35 Suppl 3():46-51. PubMed ID: 16281958
[TBL] [Abstract][Full Text] [Related]
24. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
25. Parenteral iron dextran therapy: a review.
Burns DL; Mascioli EA; Bistrian BR
Nutrition; 1995; 11(2):163-8. PubMed ID: 7647482
[TBL] [Abstract][Full Text] [Related]
26. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding.
Schröder O; Schrott M; Blumenstein I; Jahnel J; Dignass AU; Stein J
Z Gastroenterol; 2004 Aug; 42(8):663-7. PubMed ID: 15314711
[TBL] [Abstract][Full Text] [Related]
27. Hypersensitivity reactions and deaths associated with intravenous iron preparations.
Bailie GR; Clark JA; Lane CE; Lane PL
Nephrol Dial Transplant; 2005 Jul; 20(7):1443-9. PubMed ID: 15855210
[TBL] [Abstract][Full Text] [Related]
28. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
29. Parenteral iron use in the management of anemia in end-stage renal disease patients.
Bailie GR; Johnson CA; Mason NA
Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
[TBL] [Abstract][Full Text] [Related]
30. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of total dose infusion of iron dextran in iron deficiency anaemia.
Reddy CM; Kathula SK; Ali SA; Bekal R; Walsh M
Int J Clin Pract; 2008 Mar; 62(3):413-5. PubMed ID: 18005041
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
33. Parenteral iron therapy in obstetrics: 8 years experience with iron-sucrose complex.
Perewusnyk G; Huch R; Huch A; Breymann C
Br J Nutr; 2002 Jul; 88(1):3-10. PubMed ID: 12117422
[TBL] [Abstract][Full Text] [Related]
34. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products.
Charytan C; Schwenk MH; Al-Saloum MM; Spinowitz BS
Nephron Clin Pract; 2004; 96(2):c63-6. PubMed ID: 14988600
[TBL] [Abstract][Full Text] [Related]
35. Comparative rates of adverse events with different formulations of intravenous iron.
Okam MM; Mandell E; Hevelone N; Wentz R; Ross A; Abel GA
Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928
[TBL] [Abstract][Full Text] [Related]
36. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
[TBL] [Abstract][Full Text] [Related]
37. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
Sane R; Baribeault D; Rosenberg CL
Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
[TBL] [Abstract][Full Text] [Related]
38. Milk iron content in breast-feeding mothers after administration of intravenous iron sucrose complex.
Breymann C; von Seefried B; Stahel M; Geisser P; Canclini C
J Perinat Med; 2007; 35(2):115-8. PubMed ID: 17302514
[TBL] [Abstract][Full Text] [Related]
39. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
[TBL] [Abstract][Full Text] [Related]
40. Intravenous versus oral iron therapy for postpartum anaemia.
Bhandal N; Russell R
BJOG; 2006 Nov; 113(11):1248-52. PubMed ID: 17004982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]